{
  "compound": "Cannabigerol (CBG)",
  "condition": "GLAUCOMA",
  "effect_size": "Large (comparable to THC)",
  "study_type": "RCT",
  "source": "NORML:GLAUCOMA_RCT_007",
  "participants": "Animal model + 4 human subjects",
  "year": 1990,
  "notes": "Cannabigerol (CBG) for IOP Reduction: Preclinical to Clinical Translation",
  "confidence": "medium",
  "abstract": "CBG: 20-25% IOP reduction; Non-psychoactive; Comparable to THC efficacy without CNS effects"
}